PFE241227P36000
- 9.65
- 0.000.00%
Pfizer Newsroom
Pfizer Options Spot-On: On December 24th, 88,313 Contracts Were Traded, With 3.28 Million Open Interest
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
Top Midday Decliners
Enanta Pharmaceuticals to Appeal Court Ruling on Patent Infringement Case Against Pfizer
Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned
Pfizer Options Spot-On: On December 23rd, 153.55K Contracts Were Traded, With 3.73 Million Open Interest
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Pfizer's Progress on C. Diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Should Value Investors Buy Pfizer (PFE) Stock?
Pfizer Inc. (PFE) Is Attracting Investor Attention: Here Is What You Should Know
Pfizer ($PFE) Stock Has Evolved Into a Solid Income Play
Pfizer's Colorectal Cancer Combo Therapy Gains Accelerated Approval From FDA
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years?
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts
Daily short sale tracking: Palantir's short volume increased by 51 million, with a short sale ratio of 23%
The Three-year Loss for Pfizer (NYSE:PFE) Shareholders Likely Driven by Its Shrinking Earnings